| Literature DB >> 30813755 |
Gabriella Kiss1, Béla Faludi2, Brigitta Szilágyi1,3, Alexandra Makai3, Anita Velényi4, Pongrác Ács1, Péter Tardi1, Adrienn Pallag4, Viktória Bors4, Patrícia Sekk5, Melinda Járomi1.
Abstract
Our aim was to measure the venous blood flow velocity (VBFV) in case of hemiparetic patients, after passive and active thromboembolic methods, as well as the consensual effect in the hemiparetic limb following the active venous exercises in the healthy limb. We examined 215 patients, with the median age of 58.0 (55.0-63.0) years. The VBFV was measured with a HADECO BIDOP ES-100 V II type Doppler ultrasound device, using an 8 MHz head, on the femoral vein at the level of the hip joint. For statistical analysis, SPSS version 22 was used. After passive movement, on the hemiparetic side, compared to the value in resting state, the VBFV significantly (12.6; 11.6-13.5 cm/s; P < .001) increased. Following active venous exercises performed on the healthy side, the VBFV significantly (18.0; 15.6-19.6 cm/s; P < .001) increased compared to the value in resting state. Following the active venous exercises performed on the healthy side, the VBFV measured on the hemiparetic side (consensual effect) was significantly (15.1 [14.1-16.5] cm/s; P < .001) higher than the value on the hemiparetic side in resting state. Active and passive mechanical thromboprophylaxis methods can be effective. Movements of the healthy limb significantly increase the VBFV in the inactive limb, and patients can perform it themselves several times a day.Entities:
Keywords: consensual effect; mechanical thromboprophylaxis; venous blood flow velocity; venous exercise
Mesh:
Year: 2019 PMID: 30813755 PMCID: PMC6714927 DOI: 10.1177/1076029619832111
Source DB: PubMed Journal: Clin Appl Thromb Hemost ISSN: 1076-0296 Impact factor: 2.389
Characterization of the Sample.
| Examined population | 215 persons |
| Age | 58.0 (55.0-63.0) years |
| Gender | 117 males (54.5; 47.8%-61.1%) |
| Time elapsed since the diagnosis has been set up | 6-14 months |
| Time of bed rest | 13.0 (11.0-15.0) days |
| Type of stroke | 42.79% ischemic |
Figure 1.Flow diagram of how the number of participants has changed during the study.
Changes of Venous Blood Flow Velocity (cm/s) Measured in the Femoral Vein as a Result of Passive Movement in the Hemiparetic Side.a
| VBFV After Passive Movement (cm/s) |
| |||
|---|---|---|---|---|
| Hemiparetic Side (HPS) | ||||
| Median | IQR | |||
| Value in resting state (0HI) | 2.7 | 2.4 | 4.4 | |
| Time elapsed after treatment (minutes) | ||||
| 1 | 12.6 | 11.6 | 13.5 | <.001b |
| 2 | 12.8 | 11.5 | 13.3 | <.001b |
| 3 | 12.3 | 10.8 | 12.9 | <.001b |
| 4 | 11.6 | 10.5 | 12.2 | <.001b |
| 5 | 10.4 | 9.8 | 11.9 | <.001b |
| 6 | 10.1 | 9.6 | 10.7 | <.001b |
| 7 | 9.6 | 9.3 | 10.4 | <.001b |
| 8 | 9.2 | 8.8 | 10.0 | <.001b |
| 9 | 8.8 | 8.4 | 9.5 | <.001b |
| 10 | 8.3 | 7.9 | 8.5 | <.001b |
| 15 | 7.9 | 7.4 | 8.2 | <.001b |
| Difference in passive movement (cm/s) in 1-2-3-4-5-6-7-8-9-10-15 minute | <.001c | |||
Abbreviations: HI, hemiparetic side; IQR, interquartile range; VBFV, venous blood flow velocity.
aN = 215.
bWilcoxon signed rank test.
cFriedman test using Bonferroni correction.
Figure 2.Venous blood flow velocity values after active exercises on the healthy side.
Figure 3.Venous blood flow velocity values of the consensual effect on the hemiparetic side after active venous exercise on the healthy limb.
Values of the Venous Blood Flow Velocity Following the Treatment.
| Venous Flow Velocity Measurements Among Healthy Participants | ||||||
|---|---|---|---|---|---|---|
| Author (Year) | Examined Population | Examination Method | Treatment Method | Resting Venous Blood Flow Velocity Before Treatment | Venous Blood Flow Velocity After Treatment | Results/Differences |
| Passive Techniques | ||||||
| Pouran D. Faghri (1998)[ | 10 healthy volunteers (6 women, 4 men; 20 legs), mean age: 26.5 ± 5.27 years | Air plethysmograph (APG): | Voluntary exercise protocol (VOL) | – | Residual volume fraction: |
|
| G. M. Lyons (2002)[ | 10 healthy adult males, mean age: 23.9 ± 1.8 years | Acuson 128XP/10c US system, popliteal vein (pop.v) | Neuromuscular electrical stimulation (NMES): | 12 cm/s | 43 cm/s (206%) |
|
| James J. Czyrny (2010)[ | 40 healthy participants, age: between 50 and 80 years | Bilaterally used Doppler US device, pop.v, femoral vein | Electrical foot stimulation | – | – | Femoral venous blood flow: IPC vs ES |
| M. Izumi (2010)[ | 10 healthy volunteers, age: between 22 and 48 years | ALOKA Prosound a10 (ALOKA, Tokyo, Japan) Duplex US system, pop.v | Thromboprophylactic transcutaneous electrical nerve stimulation (TpTENS) | 26 (19-38) cm/s | 102 (49-148) cm/s |
|
| Barry J. Broderick (2013) | 11 patients (4 males, 7 females) who had undergone unilateral total hip replacement surgery on the day previous to the study, mean age: 69.5 ± 8.1 years | Duplex Doppler US, pop.v | 4-hour NMES session of the calf muscles | Operated limb: 12 ± 5.9 cm/s | 22.5 ± 16.8 cm/s (99%) |
|
| Barry J Broderick (2014)[ | 30 healthy participants (21 males and 9 females), mean age: 21 ± 1.08 years | Duplex Doppler US, pop.v | IPC on foot and calf | – | Foot: 50.5 (35-67) cm/s |
|
| Kaori Toya (2016)[ | 10 healthy males | Pulse Doppler method with a diagnostic US system (ACUSON P300, Siemens Healthcare, Erlangen, Germany), common femoral vein (CFV) | Supine with leg-up | – | Time-averaged maximum flow velocity (TAMV): | Supine vs head-up: |
| Alicia Martínez-Rodríguez (2018)[ | 24 healthy university students (12 males, 12 females), age: between 18 and 39 years | Doppler US, common peroneal nerve, and soleus muscle | TENS 2 sequences on peroneal nerve, the 3 on soleus muscle | 1 Hz: 13.4 (10.5-18.3) cm/s | 1 Hz: 39.93 (34.01-45.86) |
|
| Active Techniques | ||||||
| D. H. Sochart (1999)[ | 20 participants (18 men; 2 women), 40 limbs, median age: 27 years (20-54) years | Color-flow Duplex US, CFV | Supine with the leg in the apparatus, 3 types of exercise were then carried out, both passively and actively | 44.5 (40.9-48.4) cm/s | Passive flexion: 53.8 (49.5-58.5) cm/s |
|
| Benkő (2002)[ | 20 persons (9 males, 11 females), mean age: 39.9 years | Pulsed, color Doppler method, femoral vein | Arteriovenous impulse pump or leg pump | 9.7 cm/s | 16.1 cm/s, (66.9%) |
|
| Oh-Yun Kwon (2003)[ | 20 healthy male participants, average age: 21.3 years | Duplex advanced Doppler, femoral vein | Quiet breathing while resting (QR) | 0.96 (0.91-0.98 cm/s | 10.1 ± 4.2 cm/s |
|
| Paul D. Stein (2009)[ | 20 healthy volunteering males, average age: 28 ± 3 years | Philips iU22 type Doppler US (Bothell, Washington), pop.v | Ankle dorsal flexion exercises | Supine rest: | Supine exercise: 24 (20-28) cm/s |
|
| M. Griffin (2010)[ | 24 healthy volunteers (12 males, 12 females), mean age: 8 from each of 3 age groups (18-30, 31-50, 51-61) years | Doppler %%US, IU22 ultrasonic scanner (Philips Medical, Seattle, Washington), pop.v | VEINOPLUS_ stimulator is a CE-certified and FDA cleared, portable, battery (9 V) powered device | 10 cm/s | 96-105 cm/s |
|
| Sekk (2015)[ | 42 healthy persons, average age: 23, 4 years | HADECO BIDOP ES 100 V II type Doppler US device, femoral vein | Venous exercise | 10.1 (8.0-13.2) cm/s | 15.1 (10.2-20.1) cm/s (49.0%) |
|
| Yukiyo Shimizu (2017)[ | 8 healthy participants (5 men, 3 women), mean age: 21.6 ± 2.3 years | EUB 7500 (Hitachi, Tokyo, Japan), femoral vein | A novel leg exercise apparatus (LEX) | – | Increase: |
|
| Christopher R. Lattimer (2018)[ | 12 healthy volunteers (9 men, 3 females), mean age: 46 (31-59) years | APG (ACI Medical LLC, San Marcos, California), common peroneal nerve | Tip-toe maneuver (TTM) | – | Ejection fraction: |
|
| Keisuke Nakanishi (2018)[ | 9 young healthy males (mean age: 22.8 ± 3.6 years) and 18 healthy elderly males (mean age: 70.0 ± 4.6 years) | Pulsed Doppler US, femoral vein | Forced deep breathing | – | – | PBVFV change ratio for 3 breathing rates in the sitting position for the young patients (15 breaths/min: 415%, 5 breaths/min: 475%, 3 breaths/min: 483%), elderly patients at 3 breaths/min (449%) was significantly higher than that at 15 breaths/min (284%). |
| Consensual effect | ||||||
| Sekk (2015)[ | 42 healthy persons, average age: 23,4 years | HADECO BIDOP ES 100 V II type Doppler US device, femoral vein | Venous exercise | 10.1 (8.0-13.2) cm/s | 12.9 cm/s (21.5%) |
|
| Venous Flow Velocity Measurements Among Hospitalized Participants | ||||||
| Author (Year) | Examined Population | Examination Method | Treatment Method | Resting Venous Blood Flow Velocity Before Treatment | Venous Blood Flow Velocity After Treatment | Results/Differences |
| Passive Techniques | ||||||
| M. Izumi (2010)[ | 10 healthy volunteers, age: between 22 and 48 years | ALOKA Prosound a10 (ALOKA, Tokyo, Japan) Duplex US system, pop.v | Active motion of the ankle | 26 (19-38) cm/s | 75 (40-152) cm/s |
|
| Paul D Stein (2014)[ | 26 hospitalized medical patients, average age: 59 ± 17 years | Pulsed wave Doppler, Philips iU22 US system (Bothell, Washington), right popliteal and femoral veins | Before and during the application of thigh-length-fitted venous GCS, thigh-length Thrombo Embolic Deterrent (TED) stockings (Kendall, Tyco Healthcare Group LP, Mansfield, Massachusetts) | Femoral vein: 21.6 (5.4-37.9) cm/s | 23.0 (1.9-44.1) cm/s |
|
| Masahiro Ojima (2017)[ | 14 patients (10 males, 4 females), average age: 70.0 (51.0–79.0) years, 3 trauma, 3 stroke, 2 sepsis, 2 others | Philips CX50 CompactXtreme ultrasonic scanner (Philips Medical), pop.v and CFV | EMS | Right pop.v: 10.2 (7.6–14.0) cm/s | Right pop.v: 24.3 (15.1–40.8) cm/s |
|
| Barry J Broderick (2013) | 9 patients (4 males, 7 females), average age: 69.5 ± 8.1 years | Duplex Doppler US, pop.v | NMES (PALS UltraStim, Axelgaard Manufacturing Co, Ltd, California) | Peak venous velocity resting | Peak venous velocity after NMES |
|
| Dapeng Wang (2018)[ | 51 patients who ever received intermittent pneumatic compression device (IPCD) and stockings during major orthopedic surgery were taken as the experimental group (29 males, 22 females), average age: 55.6 ± 14.2 years | Doppler sonography (Sonoline Antares, Siemens Sector Healthcare), femoral vein | Routinely anticoagulant therapy via intraperitoneal injection (Fraxiparine, 0.4 mL, GlaxoSmithKline) | Prior treatment: | Post-treatment: 149.56 ± 26.35 mm/s |
|
Abbreviations: FDA, Food and Drug Administration; PBVFV, peak blood velocity in the superficial femoral vein; US, ultrasound.